Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Efficacy of Major Depressive Disorder Treatment Vortioxetine Shown in Three of Four PIII Studies: Takeda and Lundbeck
May 23, 2013
- AZ Oncology Division to Provide Information Based on Patients’ Lifestyle
May 22, 2013
- Apo Plus Station Eyes Sales Force of 300 for Established Products
May 22, 2013
- Domestic Sales of Ethical Drugs Rose 0.3% to 9,560.1 Billion Yen in FY2012: IMS Japan
May 22, 2013
- GSK Shares Clinical Trial Data with Researchers before Statistical Analysis
May 22, 2013
- Major Dispensing Pharmacy Chain Operators Expect Record High Sales and Profits in FY2013
May 21, 2013
- Five Major Dispensing Pharmacy Chain Operators’ Profits Down Due to NHI Price Revision
May 21, 2013
- Allegra AGs Pitched as Affordable Original Drugs with Production by Sanofi
May 21, 2013
- ALS Treatment Ozanezumab Designated as Orphan Drug: GSK
May 21, 2013
- AZ, BMKK Launch Once-Weekly GLP-1 Receptor Agonist Bydureon
May 20, 2013
- Takeda Slips to 3rd Place in 25 Major Pharmas’ Operating Profit Ranking
May 20, 2013
- Takeda’s Novel Diabetes Treatment GPR40 Shows Efficacy in Japanese Patients in PIII Trial
May 20, 2013
- New Rules on Settai Resulted in Fewer Serious Violations of Fair Competition Code in FY2012: Industry FTC
May 20, 2013
- 3 Major Generic-Only Makers Offer Mixed Views on Govt Promotion Measures
May 17, 2013
- FY2012 Sales Up 18% for Both Generic-Only Makers, Research-Driven Pharmas’ Generic Units; Govt Incentive Measures Biggest Contributor
May 17, 2013
- Toyama Chemical to License Novel Macrolide Agent from Cempra
May 17, 2013
- Yakult to File Elplat for New Indications of Pancreas and Gastric Cancer
May 17, 2013
- Astellas to File NDA for Enzalutamide in Japan in 1st Half of FY2013
May 17, 2013
- FY2012 Japan Pharma Market: Sales of Major Long-Listed Drugs Tumble 30-40%
May 16, 2013
- Astellas to Reorganize Research Functions, Shut Down US Subsidiaries
May 16, 2013
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…